Figure 4 | Blood Cancer Journal

Figure 4

From: CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission

Figure 4

Autologous ADCC assays. (a) NK-mediated lysis of cells from Pt.130429 was assessed in cells treated with CSL362 or the control antibody BM4. There was an ~80% reduction in blasts in the CSL362 as compared with BM4-treated population. (b) No blast depletion was observed in 2of 20 samples. To summarize the data from 18 samples, the degree of killing with autologous NKs ranged from 30–90%, with no statistical difference between the three gating strategies.

Back to article page